4Moving, a Lille, France-based clinical-stage biotechnology company, has raised €12 million in a funding round.
The investors have not been disclosed.
This funding round brings the company’s total raised to €30 million.
Read More:BotGauge AI Raises $2M in Funding
The company plans to use the funds to grow its operations and research and development efforts.
This funding comes from private investors and family offices, who strengthened their commitment by investing directly in 4MB. The round combines equity, and loans providing a flexible structure to support long term growth.
This funding builds on the €7.6 million France 2030 i-Démo grant announced last year and the recent expansion of the INFLAM-MOTION Phase 2a clinical study to the US, strengthening 4MB’s ability to advance its lead DMOAD program for knee osteoarthritis.
4Moving Biotech (4MB), a clinical-stage biotech spin-off of 4P-Pharma, is developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis. The company has raised around €30 million to date through private funding and non-dilutive public support. This reflects 4P-Pharma’s long-term strategy, leveraging its proprietary drug regeneration model to tackle serious unmet medical needs through its subsidiaries.
“The addition of new investors in 4MB shows the strength of the 4P-Pharma group’s platform, built on careful capital use and scientific rigor,” said Revital Rattenbach, CEO of 4P-Pharma and co-founder of 4MB. “By letting our subsidiaries shape and follow their own paths, 4P-Pharma proves the value of its start-up studio model.
“With this funding secured, we are well-positioned to reach our next milestone by generating strong Phase 2a data, achieving proof-of-concept, and creating strategic options for the next stages of development to help the 374 million people worldwide living with osteoarthritis,” said Luc Boblet, CEO of 4MB.
In the coming months, 4MB will focus on advancing its clinical strategy, preparing for future regulatory interactions, and making its treatment accessible to patients who need it most.
About 4Moving
Founded in 2020 by Luc Boblet and Revital Rattenbach as a spin-off of 4P-Pharma, 4Moving Biotech (4MB) is a clinical-stage biotech company developing disease-modifying drugs for osteoarthritis, a chronic condition affecting over 600 million people with no approved therapies that change its course. Based at the Pasteur Institute campus in Lille, 4MB aims to provide safe and effective treatments for patients with high unmet medical needs.
Read More:Sentra.app Raises $5M in Seed Funding
